Activity of Crizotinib in Patients with ALK-aberrant Relapsed/Refractory Neuroblastoma: A Children’s Oncology Group Study (ADVL0912)

PURPOSE: Anaplastic lymphoma kinase (ALK) aberrations are a promising target for patients with neuroblastoma. We assessed the activity of first generation ALK inhibitor crizotinib in patients with no known curative treatments and whose tumors harbored an activating ALK alteration. PROCEDURES: Twenty...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Foster, Jennifer H., Voss, Stephan D., Hall, David, Minard, Charles G., Balis, Frank M., Wilner, Keith, Berg, Stacey L., Fox, Elizabeth, Adamson, Peter C., Blaney, Susan M., Weigel, Brenda J., Mossé, Yael P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8254744/
https://ncbi.nlm.nih.gov/pubmed/33568345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4224
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados